Literature DB >> 23430570

Intentional rechallenge: does the benefit outweigh the risk?

Vid Stanulović1, Mauro Venegoni, Brian Edwards.   

Abstract

Rechallenge is defined as the readministration of a medication suspected of being a possible cause of an adverse reaction and which has been discontinued as result. It may be unintentional when the appearance of a reaction was initially not attributed to the medication. A rechallenge may be intentional when a prescriber decides that the benefit of rechallenge will outweigh its risk. When considering intentional rechallenge, one should take into account the benefit/risk balance of the suspected causative medication, and the benefit/risk balance of the best available alternative treatment or no treatment. Clinical knowledge is essential in benefit/risk assessment but there is currently no suitable tool to guide the decision on rechallenge. This article aims to propose points to consider in the creation of reaction-specific algorithms for risk assessment and management in the case of drug rechallenge.

Entities:  

Mesh:

Year:  2013        PMID: 23430570     DOI: 10.1007/s40264-013-0020-3

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  22 in total

1.  QT lengthening and life-threatening arrhythmias associated with fexofenadine.

Authors:  Y M Pinto; I C van Gelder; M Heeringa; H J Crijns
Journal:  Lancet       Date:  1999-03-20       Impact factor: 79.321

2.  The choice of antipsychotic drugs for schizophrenia.

Authors:  Robert Freedman
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245

3.  Add-on filgrastim during clozapine rechallenge in patients with a history of clozapine-related granulocytopenia/agranulocytosis.

Authors:  Grigori Joffe; Saana Eskelinen; Eila Sailas
Journal:  Am J Psychiatry       Date:  2009-02       Impact factor: 18.112

4.  Rechallenge with clozapine following leucopenia or neutropenia during previous therapy.

Authors:  Louisa R Dunk; Linda J Annan; Christopher D Andrews
Journal:  Br J Psychiatry       Date:  2006-03       Impact factor: 9.319

5.  ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis.

Authors:  B Sassolas; C Haddad; M Mockenhaupt; A Dunant; Y Liss; K Bork; U F Haustein; D Vieluf; J C Roujeau; H Le Louet
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

Review 6.  Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.

Authors:  Robert J Desnick; Roscoe Brady; John Barranger; Allan J Collins; Dominique P Germain; Martin Goldman; Gregory Grabowski; Seymour Packman; William R Wilcox
Journal:  Ann Intern Med       Date:  2003-02-18       Impact factor: 25.391

7.  Tobramycin-induced hepatotoxicity.

Authors:  Sarah A Nisly; Shaunta' M Ray; Robert A Moye
Journal:  Ann Pharmacother       Date:  2007-10-23       Impact factor: 3.154

8.  Failure of filgrastim to prevent severe clozapine-induced agranulocytosis.

Authors:  Tricia G Majczenko; Jonathan T Stewart
Journal:  South Med J       Date:  2008-06       Impact factor: 0.954

Review 9.  Update on the evaluation of hypersensitivity reactions to betalactams.

Authors:  M Blanca; A Romano; M J Torres; J Férnandez; C Mayorga; J Rodriguez; P Demoly; P J Bousquet; H F Merk; M L Sanz; H Ott; M Atanasković-Marković
Journal:  Allergy       Date:  2009-02       Impact factor: 13.146

10.  Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme.

Authors:  David Bodensteiner; C Ronald Scott; Katherine B Sims; Gillian M Shepherd; Rebecca D Cintron; Dominique P Germain
Journal:  Genet Med       Date:  2008-05       Impact factor: 8.822

View more
  2 in total

1.  Intentional rechallenge and the clinical management of drug-related problems.

Authors:  Ronald Meyboom
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

Review 2.  Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials.

Authors:  Juliana Hey-Hadavi; Daniel Seekins; Melissa Palmer; Denise Coffey; John Caminis; Sandzhar Abdullaev; Meenal Patwardhan; Haifa Tyler; Ritu Raheja; Ann Marie Stanley; Liliam Pineda-Salgado; David L Bourdet; Raul J Andrade; Paul H Hayashi; Lara Dimick-Santos; Don C Rockey; Alvin Estilo
Journal:  Drug Saf       Date:  2021-03-16       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.